Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR002215)
Formula
CYP3A4 ...
SVG example
3-Hydroxylation
Reactant Ruxolitinib phosphate Product Ruxolitinib M16 metabolite
Reactant Info Product Info
Metabolic Enzyme Cytochrome P450 3A4 (CYP3A4) DME Info
Cytochrome P450 2C9 (CYP2C9) DME Info
Metabolic Type Oxidation - 3-Hydroxylation
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR002216 Ruxolitinib phosphate Ruxolitinib M18 metabolite Oxidation - 2-Hydroxylation Ruxolitinib phosphate [1]
MR002217 Ruxolitinib phosphate Ruxolitinib M49 metabolite Unclear Ruxolitinib phosphate [1]
Other MR(s) Related to The Product of This MR
Other MR(s) That Produce The Product of This MR
MR ID Reactant Product MR Type Related Drug REF
MR002027 Phenprocoumon 8-hydroxy-R-phenprocoumon Oxidation - 8-Hydroxylation Phenprocoumon [2]
MR008879 Ruxolitinib Ruxolitinib M16 metabolite Oxidation - 3-hydroxylation Ruxolitinib [1], [3]
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR008880 Ruxolitinib M16 metabolite Ruxolitinib M9 metabolite Other reaction - Ketone formation Ruxolitinib [4]
MR002214 Ruxolitinib M16 metabolite Ruxolitinib metabolite M9 Unclear Ruxolitinib phosphate [1]
References
1 Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans Drug Metab Dispos. 2010 Nov;38(11):2023-31. doi: 10.1124/dmd.110.033787.
2 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
3 The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers
4 DrugBank(Pharmacology-Metabolism):Ruxolitinib

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.